Erika Hamilton MD, FASCO

ASCO 2025 Interview: Erika Hamilton As practicing oncologists, we can get bogged down in our individual practices and thus have trouble seeing the bigger picture in...

Recently, I had the chance to reflect on chairing #ASCO2025, the evolving landscape of breast cancer research, and why patient-centered innovation matters more than ever.

#SCRIOncologyPartners

📖 www.emjreviews.com/en-us/amj/on...
#Oncology #BreastCancer #ClinicalTrials #Leadership

These are great short summaries!

VERITAC-2 shows vepdegestrant improves PFS after CDK4/6i among pts with HR+ mutESR1 MBc, from 2.1 months to 5.0 months. @erikahamilton9.bsky.social
@oncoalert.bsky.social #ASCO25

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸

@elisaagostinetto.bsky.social‬
@erikahamilton9.bsky.social‬
@drsgraff.bsky.social‬
@elisabettabonzano.bsky.social‬

Ha- love it. We still have more Easter Eggs in breast 🐣! 😜

I'm biased, but think #ASCO25 is going to be great.

#bcsm has some great abstracts this year- #SERENA-6 1L endocrine switch w/ ESR1 for HR+, #DB-09 1L TDXd for HER-2, and #ASCENT04 1L saci + pembro for TNBC

Another positive trial in #bcsm, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer.

We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting!

@oncbrothers.bsky.social
@oncoalert.bsky.social

www.astrazeneca.com/media-centre...

Maple was very interested in the Derby 🐎

Molecular Profiling, Endocrine Sensitivity Are Key to Managing Later-Line HR+/HER2-Negative Breast Cancer Erika P. Hamilton, MD, discusses the current role of CDK4/6 inhibitors and evolving targeted therapies in advanced HR-positive, HER2-negative breast cancer.

Molecular Profiling, Endocrine Sensitivity Are Key to Managing Later-Line HR+/HER2-Negative Breast Cancer @erikahamilton9.bsky.social #bcsm #oncology www.onclive.com/view/molecul...

Right?!?

Look at what our practice did for us for Doctor's Day this year? Seriously so cute and thoughtful.

Definitely my best Doctor's Day ever! Thank you SCRI Oncology Partners!

#JSMO25 was amazing!

💪🏼 Had a fantastic session led by Makiko Ono on gender balance in oncology,

⭐️ a great joint @ascocancer.bsky.social / JSMO session on undruggable targets,

🌹 a beautiful Presidential Dinner....

🇯🇵 and got to squeeze in a visit to a shrine!

It's almost like we knew we didn't want measles and all were getting vaccinated so we didn't have to live like it was in 1950 🤷🏼‍♀️

PSA: anti-vax isn't cool, it isn't protecting your family. You and your family don't want complications from diseases that can be prevented.

It was for people who did not have progression on scan yet, but the emergence of a new mutation. So signaling progression was coming.

The sum of PFS and PFS2 will be important to see if people are benefiting from the two lines together longer than if the switch happened at PD.

Happy to have participated in #SERENA6, using ctDNA to tailor an early switch strategy for metastatic HR+ disease.

Could make ctDNA actually ACTIONable in breast for the first time!

www.astrazeneca.com/media-centre...

Ok, any experience using? What are the side effects or drug interactions?

Asia Pacific Breast Cancer Symposium

Promotional graphic for Great Debates in Solid Tumors, highlighting its partnership with Sarah Cannon Research Institute (SCRI) and featuring four speakers. The image has a blue background with a stylized New York City skyline, including the One World Trade Center. At the top, the event's logo and SCRI branding appear. The text reads, 'Join us in New York City, March 22–23, 2025.' Below, four headshots of speakers are displayed with their names and titles: Erika Hamilton, MD (Director, Breast Cancer Research Program), Kathleen Moore, MD, MS (Associate Director of Clinical Research), Vivek Subbiah, MD (Chief, Early Phase Drug Development), and Andrew McKenzie, MD (Vice President, Personalized Medicine). The design includes a mix of white, yellow, and orange text over the blue background.

Proud to collaborate with @scrinetwork.bsky.social at Great Debates in Solid Tumors!

Join Co-Chairs @erikahamilton9.bsky.social & @drkatymoore.bsky.social, plus Andrew McKenzie PhD, & @viveksubbiah.bsky.social, leading key discussions on solid tumors.

🔗 gdsolidtumors.com

#Oncology #CancerResearch

My kid has to select the proper US state as an online interactive map calls them out in random order in under 2 minutes.

I can't even come close. It's near impossible when you have to zoom in on small states in the NE to accurately press the right tiiiny state on an iPad and then zoom back out.

TODAY🚨 #OncoAlertColloquium #BreastCancer
✅FREE REGISTRATION👉 buff.ly/4jJy808

✅ACCESS👉 vimeo.com/event/4875736

⭐️A PASSWORD IS NEEDED, hence REGISTRATION IS NEEDED
@erikahamilton9.bsky.social
@hoperugo.bsky.social
@drsgraff.bsky.social
@maryamlustberg.bsky.social
@elisaagostinetto.bsky.social

Soooooo....I guess my addictive habit of buying cheap light-up seasonal decorations from Temu for less than $5 is drying up next week, huh?

Have to admit, I've been super pleasantly surprised by this stuff.

OncoAlert🚨Network with our partners at ESSO, ESGO, MASCC & SIOG invite you to the #OncoAlertColloquium

NEXT WEEK!!

FREE REGISTRATION HERE👉 buff.ly/3CChgre
February 3-9, 2025 💯% Virtual & Interactive
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@drjnaidoo.bsky.social
@hoperugo.bsky.social

EU medicines agency quits X, moves to Bluesky The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media platform that some have criticised for its content.

This is huge.

The European equivalent to the FDA has said enough to the propaganda machine X.

Others will follow.

#medsky #oncosky

www.reuters.com/world/europe...

DB-06 #TDXD approved for HER-2 "ultra low" (IHC but staining) breast cancer, and 1st line moving this drug up.

#bcsm
@oncoalert.bsky.social

www.astrazeneca.com/media-centre...

Hmmmm, wonder if it's pretty insurance dependent. May try again at month two for her.

Yes, Some Vaccines Contain Aluminum. That’s a Good Thing. R.F.K. Jr. and others have blamed the ingredient for allergies and other illnesses. Scientists say it actually bolsters the immune response.

The tiny amount of aluminum helps make certain vaccines even more effective& has a strong safety record. “In the first six months of babies’ lives, vaccines expose them to roughly 4.4 milligrams of aluminum. One slice of American cheese, by contrast, can contain as much as 50 milligrams of aluminum”

Anyone need motivation for a flu shot?

My middle school daughter's basketball game for today was postponed to next week because the opposing team doesn't have 5 players to dress that don't currently have the flu. 😷

Fantastic thread about why freezing the NIH has far reaching consequences.

Yes, I have to confirm this is completely normal. Been through this stage x 2.

In better news, it tends to go away in half a year.

US FDA approves AstraZeneca's drug for breast cancer The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday.

Hot off the press 📰 - we have a 2nd TROP-2 ADC for #bcsm

Saci: D#1,8
-💩 low WBC

Dato: q3 wks
- 👄 sores

Nice to have options for our patients

@oncoalert

www.reuters.com/business/hea...

Who has tried to add Palbo to maintenance let + HP?

Know it isn't "approved yet", but wasn't successful. Anyone been successful for coverage yet with #PATINA?

@ptarantinomd.bsky.social
@hoperugo.bsky.social
@stolaney1.bsky.social
@vkaklamani.bsky.social
@jochien.bsky.social